Atherosclerosis-related markers in systemic lupus erythematosus patients: The role of humoral immunity in enhanced atherogenesis

Lupus

Volumn 8, Issue 3, 1999, Pages 220-226

  George, J ^a   Harats, D ^a   Gilburd, B ^a   Levy, Y ^a   Langevitz, P ^a   Shoenfeld, Y ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Atherosclerosis; Autoimmunity; Immune complexes; OxLDL; SLE

Indexed keywords

AUTOANTIGEN; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPROTEIN A; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMORAL IMMUNITY; LIPID METABOLISM; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0032945996     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120399678847597     Document Type: Article

References (41)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
2. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest 1991; 64: 5-11.
3. Wick G, Schett G, Auberger A et al. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995; 16: 27-33.
4. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994; 344: 793-795.
5. Salonen JT, Hertualou S, Yamamoto R et al. Antibodies against oxidized LDL and the progression of carotid atherosclerosis. Lancet 1992; 339: 883-887.
6. Puurunen M, Mantarr M, Manuialen V et al. Antibodies against oxidized low density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-2609.
7. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) deficient rabbits with homologeous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92: 821-825.
8. Ameli SA, Hultgardh-Nilsson, Regenstrom J et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074-1079.
9. George J, Akrek A, Gilburd B et al. Hyperimmuinization of apoE deficient mice with homologous MDA-low density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138: 147-152.
10. Vaarala O, Alfthau G, Jauhiainen M et al. Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-925.
11. Galli M, Comfurious MP, Maassen C et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547.
12. George J, Apek A, Gilburd B et al. Atherosclerosis in LDL receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus 1997; 6: 723-729.
13. George J, Aprek A, Gilburd B et al. Induction of early atherosclerosis in LDL receptor deficient mice immunized with β2 glycoprotein I. Circulation 1998; 15: 1108-1115.
14. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1988; 85: 2805-2809.
15. 2 in tissue slices from atherosclerotic carotid plaque. Arteriscler Thromb Vasc Biol 1997; 17: 2257-2263.
16. Wu R, Huang YH, Elinder LS, Frostegard J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol 1998; 18: 626-630.
17. Welch WJ. Mammalian stress response: cell physiology, structure-/function of stress proteins, and implications for medicine and disease. Physiol Rev 1992; 72: 1063-1081.
18. Xu Q, Willeit J, Marosa M et al. Induction of arteriosclerosis in normocholesterolemic mice rabbits by immunization with heat shock protein 65. Arterioscler Thombosis 1992; 12: 789-799.
19. Xu Q, Willeit J, Marosa M et al. Association of serum antibodies to heat shock protein 65 with carotid atherosclerosis. Lancet 1993;341:255-259.
20. Schett G, Xu Q, Amberger A et al. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest 1995; 96: 2569-2577.
21. Schett G, Metzler B, Mayr M et al. Macrophage lysis mediated by autoantibodies to heat shock protein 60/65. Artherosclerosis 1997; 128: 27-38.
22. Tsakraklidesm VG, Blieden IC, Edwards JE. Coronary atherosclerosis and myocardial infarction associated with systemic lupus erythematosus. Am Heart J 1974; 87: 637-641.
23. Jonsson H, Nived O, Sturfelt G. Outcome of systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989; 68: 141-150.
24. MacGregor A et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 152-155.
25. Borba EF, Santos RD, Bonfa E et al. Lipoprotein (a) levels in systemic lupus erythematosus. J Rheumatol 1994; 21: 220-223.
26. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1279.
27. George J, Blank M, Hojnik M et al. Oxidized low density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome. Clin Exp Immunol 1997; 108: 227-233.
28. Maggi E, Bellazzi R, Gazo A et al. Autoantibodies against oxidatively modified LDL in uremic patients undergoing dialysis. Kidney Int 1994; 46: 869-876.
29. Kiener PA, Ranklin BM, Davis PM et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler Thromb Vasc Biol 1995; 15: 990-999.
30. Virella G, Munoz JF, Galbraith GM et al. Activation of human monocyte derived macrophages by immune complexes containing low density lipoprotein. Clin Immunol Immunopathol 1995; 75: 179-189.
31. Gisinger C, Lopes-Virella MF. Lipoprotein immune complexes and diabetic vascular complications. Diabetes 1992; Suppl 2: 92-96.
32. Mironova M, Virella G, Virella-Lowell I et al. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin Immunol Immunopathol 1997; 85: 73-82.
33. Festa A, Kopp HP, Schernthaner G et al Autoantibodies to oxidised low density lipoprotein are inversely related to metabolic control and microvascular complications. Diabetologia 1998; 41: 350-356.
34. Kabakov AE, Tertov VV, Saence VA et al. The atherogenic effect of lupus sera: systemic lupus erythematosus derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol 1992; 63: 214-220.
35. N Bostom AG, Cupples LA, Jenner JL et al. Elevated plasma Lp(a) and coronary heart disease in men aged 55 years and younger-a prospective study. JAMA 1996; 276: 544-548.
36. Nachman RL. Thrombosis and atherogenesis-molecular connections. Blood 1992; 79: 1897-1906.
37. Sorensen KE, Celermajer DS, Georgakopoulos et al. Impairment of endothelium-dependent dilatation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein (a) level. J Clin Invest 1994; 93: 50-55.
38. 2 activity and antilipocortin antibodies in systemic lupus erythematosus correlative study with disease activity. J Rheumatol 1994; 21: 252-257.
39. Simantov R, LaSala JM, Lo SK et al. Activation of cultured endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-2219.
40. George J et al. Differential effects of anti-β2GPI antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998; 97: 900-906.
41. Luliano L, Pratico D, Ferro D et al. Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. Blood 1997; 90: 3931-3935.